The Joint Venture Collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. The transaction combines Grünenthals unrivaled expertise in pain management with Kyowa Kirin’s portfolio of valuable medicines anchored in pain management.
The total revenues of the portfolio in 2021 were €200 million. The products are marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide. Grünenthal intends to acquire 100% the portfolio at the beginning of 2026.
